Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06544577

Safety of Elacestrant in ER+/HER2- and ESR1 Mutations MBC

Sponsor: SciClone Pharmaceuticals

View on ClinicalTrials.gov

Summary

This study is a prospective non-interventional real-world study enrolling patients with advanced breast cancer who are ER+/HER2- and have ESR1- gene mutations, collecting information on patients' complaints, physical examination, laboratory tests, imaging tests and adverse events to observe the safety of elacestrant treatment.

Official title: Safety of Elacestrant in the Treatment of Advanced Breast Cancer Patients With ER+/HER2- and ESR1-mutations Who Have Progressed on at Least One Line of Endocrine Therapy: a Prospective, Non-interventional Real-world Study

Key Details

Gender

FEMALE

Age Range

18 Years - Any

Study Type

OBSERVATIONAL

Enrollment

350

Start Date

2024-07-13

Completion Date

2026-08-01

Last Updated

2024-08-09

Healthy Volunteers

No

Interventions

DRUG

ELacestrant

345 mg/day once daily oral dosing

Locations (1)

Hainan Hospital of Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine (Boao Research Hospital, Hainan)

Qionghai, Hainan, China